[go: up one dir, main page]

MX2018012866A - Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion. - Google Patents

Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion.

Info

Publication number
MX2018012866A
MX2018012866A MX2018012866A MX2018012866A MX2018012866A MX 2018012866 A MX2018012866 A MX 2018012866A MX 2018012866 A MX2018012866 A MX 2018012866A MX 2018012866 A MX2018012866 A MX 2018012866A MX 2018012866 A MX2018012866 A MX 2018012866A
Authority
MX
Mexico
Prior art keywords
expression
methods
compositions
antibodies based
making antibodies
Prior art date
Application number
MX2018012866A
Other languages
English (en)
Inventor
Chen Gang
Babb Robert
Burakov Darya
P Fandl James
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2018012866A publication Critical patent/MX2018012866A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta invención se refiere a la integración específica de sitio y la expresión de proteínas recombinantes en células eucariotas. En particular, la invención incluye composiciones y métodos para la expresión mejorada de anticuerpos lo que incluye anticuerpos biespecíficos en células eucariotas, particularmente líneas celulares de hámster chino (Cricetulus griseus), mediante el uso de un locus potenciador de la expresión.
MX2018012866A 2016-04-20 2017-04-20 Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion. MX2018012866A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325385P 2016-04-20 2016-04-20
PCT/US2017/028552 WO2017184831A1 (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of an expression-enhancing locus

Publications (1)

Publication Number Publication Date
MX2018012866A true MX2018012866A (es) 2019-03-11

Family

ID=58701850

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012866A MX2018012866A (es) 2016-04-20 2017-04-20 Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion.
MX2024014381A MX2024014381A (es) 2016-04-20 2018-10-19 Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024014381A MX2024014381A (es) 2016-04-20 2018-10-19 Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion

Country Status (15)

Country Link
US (2) US11530277B2 (es)
EP (1) EP3445780A1 (es)
JP (3) JP7134868B2 (es)
KR (2) KR102474757B1 (es)
CN (2) CN109071633B (es)
AR (1) AR108295A1 (es)
AU (2) AU2017253240B2 (es)
BR (1) BR112018071285A2 (es)
CA (1) CA3015371A1 (es)
EA (1) EA201892137A1 (es)
IL (2) IL309065A (es)
MX (2) MX2018012866A (es)
SG (2) SG11201807881VA (es)
TW (1) TW201803981A (es)
WO (1) WO2017184831A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017184831A1 (en) 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
IL275462B1 (en) 2017-12-22 2025-09-01 Genentech Inc Targeted integration of nucleic acids
WO2020034097A1 (en) * 2018-08-14 2020-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Transcriptional regulatory element and its use in enhancing the expression of exogenous protein
SG11202103334YA (en) * 2018-10-26 2021-05-28 Hoffmann La Roche Multispecific antibody screening method using recombinase mediated cassette exchange
JP7674245B2 (ja) * 2018-12-21 2025-05-09 ジェネンテック， インコーポレイテッド 核酸の標的化組込み
SG11202109391PA (en) * 2019-03-29 2021-09-29 Hoffmann La Roche Method for the generation of an fcrn expressing cell by targeted integration of multiple expression cassettes in a defined organization
AU2020252840B2 (en) 2019-04-02 2025-01-23 Chugai Seiyaku Kabushiki Kaisha Method of introducing target-specific foreign gene
EP3986924A1 (en) * 2019-06-19 2022-04-27 F. Hoffmann-La Roche AG Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
KR20220024637A (ko) * 2019-06-19 2022-03-03 에프. 호프만-라 로슈 아게 정의된 조직의 다수 발현 카세트들의 표적화 통합에 의한 3가 항체 발현 세포의 생성 방법
JP2022537202A (ja) * 2019-06-19 2022-08-24 エフ．ホフマン－ラ ロシュ アーゲー 所定の構成の複数の発現カセットの標的指向性組込みによって多価二重特異性抗体発現細胞を作製するための方法
MX2021015538A (es) * 2019-06-19 2022-02-10 Hoffmann La Roche Metodo para la generacion de una celula que expresa un anticuerpo biespecifico bivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.
CN114080451B (zh) * 2019-06-19 2024-03-22 豪夫迈·罗氏有限公司 通过使用Cre mRNA进行的靶向整合来产生蛋白质表达细胞的方法
KR20220025806A (ko) * 2019-06-26 2022-03-03 제넨테크, 인크. 핵산의 무작위 구성 표적화 통합
EP4087925A2 (en) * 2020-01-10 2022-11-16 F. Hoffmann-La Roche AG Method for the assembly of large nucleic acids from short fragments
KR20240117146A (ko) * 2021-12-22 2024-07-31 제넨테크, 인크. 다중 벡터 재조합효소 매개 카세트 교환
US20250122482A1 (en) 2023-09-07 2025-04-17 Regeneron Pharmaceuticals, Inc. Production and purification of covalently surface modified adeno-associated virus
CN119955730A (zh) * 2023-11-08 2025-05-09 深圳太力生物技术有限责任公司 一种细胞株及其制备方法与应用
WO2025111473A1 (en) 2023-11-21 2025-05-30 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
AU2001294088B2 (en) 2000-08-07 2006-09-07 Serono Genetics Institute S.A. Schizophrenia related gene and protein
GB0209884D0 (en) 2002-04-30 2002-06-05 Ares Trading Sa Proteins
AU2003237259B2 (en) 2002-05-29 2008-01-24 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
CA2504595A1 (en) 2002-11-14 2004-06-03 Lynne Krummen Intron fusion construct and method of using for selecting high-expressing production cell lines
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
EP2115136A4 (en) 2006-12-21 2010-05-19 Glaxosmithkline Llc NOVEL PROCEDURE
WO2008089396A1 (en) 2007-01-19 2008-07-24 Invitrogen Corporation Compositions and methods for genetic manipulation and monitoring of cell lines
EP2139924B1 (en) 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof
EP2150617B1 (en) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
JP5744856B2 (ja) 2009-06-02 2015-07-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． フコシル化欠損細胞
KR20120027055A (ko) 2009-06-26 2012-03-20 리제네론 파라마큐티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
JP6091894B2 (ja) 2009-09-16 2017-03-15 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
CA2796181C (en) 2010-04-20 2023-01-03 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2711428A1 (en) * 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI675044B (zh) 2012-11-14 2019-10-21 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MX2017005306A (es) * 2014-10-23 2018-01-09 Regeneron Pharma Novedosos sitios de integracion en celulas cho y usos de estos.
SMT202200050T1 (it) 2015-09-23 2022-03-21 Regeneron Pharma Anticorpi bispecifici anti-cd3 ottimizzati e loro usi
WO2017184831A1 (en) 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus

Also Published As

Publication number Publication date
MX2024014381A (es) 2024-12-06
IL309065A (en) 2024-02-01
US20230322956A1 (en) 2023-10-12
US20190263937A1 (en) 2019-08-29
CA3015371A1 (en) 2017-10-26
JP7789143B2 (ja) 2025-12-19
US12503520B2 (en) 2025-12-23
EP3445780A1 (en) 2019-02-27
JP2022164824A (ja) 2022-10-27
JP2024164196A (ja) 2024-11-26
JP7134868B2 (ja) 2022-09-12
JP2019514358A (ja) 2019-06-06
CN116004544A (zh) 2023-04-25
AR108295A1 (es) 2018-08-08
CN109071633B (zh) 2022-11-18
IL262268B2 (en) 2024-05-01
CN109071633A (zh) 2018-12-21
IL262268A (en) 2018-11-29
EA201892137A1 (ru) 2019-03-29
KR102474757B1 (ko) 2022-12-07
JP7546015B2 (ja) 2024-09-05
AU2017253240B2 (en) 2024-07-04
KR20210135340A (ko) 2021-11-12
BR112018071285A2 (pt) 2019-02-12
SG11201807881VA (en) 2018-10-30
AU2017253240A1 (en) 2018-09-20
IL262268B1 (en) 2024-01-01
US11530277B2 (en) 2022-12-20
SG10202010156XA (en) 2020-11-27
TW201803981A (zh) 2018-02-01
WO2017184831A1 (en) 2017-10-26
KR20180134894A (ko) 2018-12-19
AU2024220126A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
MX2024014381A (es) Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion
MX2025003852A (es) Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion
PH12018501456A1 (en) Chimeric proteins and methods of regulating gene expression
ZA202308519B (en) Anti-vegf protein compositions and methods for producing the same
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MY199937A (en) Steroids and protein-conjugates thereof
EP4331605A3 (en) Methods and compositions comprising purified recombinant polypeptides
MX2021014712A (es) Polipeptidos de transposasa y sus usos.
EP4279136A3 (en) Methods for determining car-t cells dosing
MX2021010668A (es) Proteinas de fusion de citoquinas.
EP4368702A3 (en) Method of enhancing rna expression in a cell
MY183188A (en) Non-human animals having a humanized b-cell activating factor gene
MX363690B (es) Expansión de celulas madre adultas in vitro.
EA201791275A1 (ru) Способы получения ctp-модифицированных полипептидов длительного действия
EA201791918A1 (ru) Модификация белков клеток-хозяев
EA201892588A1 (ru) Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации
EP3543335A3 (en) Soluble intein fusion proteins and methods for purifying biomolecules
WO2014150748A3 (en) Stabilized single human cd4 domains and fusion proteins
MX2020001223A (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas.
WO2016011448A3 (en) Methods and compositions for expression of polypeptides in a cell
EP4467565A3 (en) Anti-tnf alpha antibody formulations
MX2021009154A (es) Selectividad eficaz de proteinas recombinantes.
WO2017079656A3 (en) Artificial proteins and compositions and methods thereof